Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →
Aurobindo Pharma Limited — Q3 FY24
Aurobindo Pharma reported Q3 FY24 revenue of INR 7,352 crore (+14.7% YoY) and EBITDA margin of 21.8%, driven by strong US formulation growth (+28.9% YoY) and injectable/specialty revenue surging 58% YoY to $112M, partly from Revlimid.
bullish
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Aurobindo Pharma reported Q3 FY24 revenue of INR 7,352 crore (+14.7% YoY) and EBITDA margin of 21.8%, driven by strong US formulation growth (+28.9% YoY) and injectable/specialty revenue surging 58% YoY to $112M, partly from Revlimid. PAT grew 19.6% YoY to INR 936 crore. Management reiterated FY24 EBITDA margin target of 20%, supported by cost efficiencies and new product launches. However, Eugia Unit III received an FDA Form 483 with 9 observations, leading to a temporary manufacturing pause and an estimated $20M revenue impact in Q4. Biosimilar pipeline advances with trastuzumab approval in India and Phase III trials for omalizumab. Key risk: prolonged Eugia Unit III shutdown could erode market share in injectable products.
ऑरोबिंदो फार्मा ने तीसरी तिमाही में 7,352 करोड़ रुपये की कमाई की, जो पिछले साल से 14.7% ज्यादा है। कंपनी का मुनाफा 936 करोड़ रुपये रहा, जो 19.6% बढ़ा। अमेरिका में दवाओं की बिक्री 28.9% बढ़ी, खासकर इंजेक्शन और खास दवाओं से 58% ज्यादा कमाई हुई। कंपनी ने साल भर में 20% मुनाफा कमाने का लक्ष्य रखा है। लेकिन यूजिया यूनिट III में एफडीए ने 9 खामियां पाईं, जिससे उत्पादन रुक गया और अगली तिमाही में 20 करोड़ डॉलर का नुकसान हो सकता है। कंपनी कैंसर और एलर्जी की नई दवाओं पर काम कर रही है। अगर यूजिया यूनिट जल्दी नहीं खुली, तो इंजेक्शन बाजार में हिस्सेदारी घट सकती है।
Promises0 met · 3 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Eugia Unit III FDA observations and production halt
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Formulation Revenue (Constant Currency)
$451M
+27.1% YoY
US formulation revenue grew 27.1% YoY in constant currency terms, driven by volume gains and new product launches.
Injectable & Specialty Revenue
$112M
+58% YoY
Injectable and specialty business revenue increased 58% YoY, largely due to new product launches including Revlimid.
Eugia Unit III Revenue Impact
$20M
Estimated Q4 impact
Temporary manufacturing pause at Eugia Unit III due to FDA observations is expected to reduce Q4 revenue by ~$20M.
Biosimilar Xolair Revenue Target (2028)
$120M-$180M
Guidance for 2028
Management guided Xolair biosimilar revenue potential of $120M-$180M by 2028, with limited competition expected.
What Changed vs Last Quarter
NEW
Eugia Unit III production restart timeline
Non-aseptic lines expected to restart by end of February 2024; aseptic lines within 1-2 months; full production by end of FY24.
NEW
China plant revenue generation from Q1/Q2 FY25
The China oral solids plant has received cGMP approval and is expected to start generating revenue from Q1 or Q2 of FY2025.
NEW
Biosimilar Xolair revenue guidance of $120M-$180M by 2028
Management guided Xolair biosimilar revenue potential of $120M-$180M by 2028, assuming approvals in US and Europe.
UPDATED
FY24 EBITDA margin target of 20%
Management reiterated confidence in achieving 20% EBITDA margin for FY24, supported by operational efficiencies and cost improvements.
DROPPED
Eugia Specialities global revenue of $560 million for FY24
On track to achieve $560 million globally for Eugia Specialities in FY24, driven by injectable growth.
DROPPED
Pen-G plant commissioning by Q4 FY24
Pen-G plant expected to be operational by end of Q4 FY24 or early Q1 FY25, with 15,000-ton capacity.
DROPPED
Biosimilar filings in Europe by January 2024
Three biosimilars (pegfilgrastim, filgrastim, trastuzumab) to be filed in Europe by end of January 2024.
NEW RISK
Eugia Unit III FDA observations and production halt
FDA issued Form 483 with 9 observations at Eugia Unit III; manufacturing paused, expected $20M revenue impact in Q4. Risk of prolonged shutdown and market share loss.
NEW RISK
Potential market share loss in injectable products
Analyst raised concern about losing market share in key products from Eugia Unit III; management acknowledged risk but expects to recover with existing stock and phased restart.
NEW RISK
Penicillin G plant pricing risk
Analyst questioned profitability if Pen G prices fall below $20/kg; management deferred response, indicating uncertainty.
NEW RISK
Biosimilar commercialization delays
Pneumococcal vaccine missed national tender timeline; management indicated no near-term market entry, highlighting execution risk in biosimilar launches.
RISK GONE
Price erosion in US generics
While current price erosion is neutral, increased competition could pressure margins in oral solids and injectables.
RISK GONE
Execution risk in new plant ramp-ups
Pen-G, China, and biosimilar plants face commissioning delays; revenue contribution may shift to FY26.
RISK GONE
Depreciation and impairment charges
Higher depreciation due to impairment provisions may persist, impacting reported profitability.
RISK GONE
Dependence on gRevlimid for margin target
Analyst questioned if 20% margin guidance includes gRevlimid; management confirmed, but any volume/pricing shortfall could miss target.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
On track to achieve $560 million globally for Eugia Specialities in FY24, driven by injectable growth.
Fast read
Guidance and risk preview
Management reiterated confidence in achieving 20% EBITDA margin for FY24, supported by operational efficiencies and cost improvements.
FDA issued Form 483 with 9 observations at Eugia Unit III; manufacturing paused, expected $20M revenue impact in Q4.
View Risks →